Advertisement

Rheumatology International

, Volume 10, Issue 4, pp 153–158 | Cite as

The effect of gold treatment on monocyte interleukin-1 production in rheumatoid arthritis

A prospective study
  • V. A. Danis
  • A. J. Kulesz
  • D. E. Kelly
  • D. S. Nelson
  • P. M. Brooks
Article

Summary

Monocyte interleukin-1 (IL-1) production in vitro was studied in 49 patients with rheumatoid arthritis (RA) and 31 controls. Twenty-six of the RA patients were studied prospectively for up to 12 months after beginning chrysotherapy. About half of the patients (group 1) exhibited pretreatment levels of monocyte IL-1 secretion (as measured by bioassay or B-IL-1) significantly higher than that of the controls. Immunoreactive IL-1 (IR-IL-1) levels, however, were similar to controls. Clinical improvement in this group of patients was modest and transient but could be associated with a fall in the level of IL-1 (B-IL-1 and IR-IL-1) secretion. Other RA patients (group 2) appeared to have normal or reduced pretreatment levels of IL-1 secretion. Chrysotherapy resulted in significant clinical improvement within 3 months, and this was associated with an increase in IL-1 (both B-IL-1 and IR-IL-1) secretion by the patients' blood monocytes to normal or supranormal levels. Thus these two groups of RA patients (which differed only in the average duration of disease) had different prognoses in relation to chrysotherapy and the effect of chrysotherapy-induced remission on monocyte IL-1 secretion was opposite. These results suggest that monocyte IL-1 production in vitro reflects changes secondary to the anti-rheumatic effects of chrysotherapy.

Key words

Interleukin-1 Monocytes Rheumatoid arthritis Gold sodium thiomalate Auranofin 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Feldmann M, Kissonerghis AM, Buchan G et al (1988) Role of HLA class II and cytokine expression in rheumatoid arthritis. Scand J Rheumatol [Suppl] 76: 39–46Google Scholar
  2. 2.
    Yamagata N, Kobayashi K, Kasama T et al (1988) Multiple cytokine activities and loss of interleukin-2 inhibitor in synovial fluids of patients with rheumatoid arthritis. J Rheumatol 15: 1623–1627PubMedGoogle Scholar
  3. 3.
    Miyasaka N, Sato K, Goto M et al (1988) Augmented interleukin-1 production and HLA-DR expression in the synovium of rheumatoid arthritis patients. Possible involvement in joint destruction. Arthritis Rheum 31: 480–486PubMedGoogle Scholar
  4. 4.
    Eastgate JA, Symons JA, Wood NC, Grinlinton FM, Di Giovine FS, Duff GW (1988) Correlation of plasma interleukin 1 levels with disease activity in rheumatoid arthritis. Lancet II: 706–709Google Scholar
  5. 5.
    Goto M, Sasano M, Yamanaka H et al (1987) Spontaneous production of an interleukin-1-like factor by cloned rheumatoid synovial cells in long-term culture. J Clin Invest 80: 786–796PubMedGoogle Scholar
  6. 6.
    Nouri AME, Panayi GS, Goodman SM, Waugh APW (1985) Cytokines in rheumatoid arthritis: production of IL-1. Br J Rheumatol [Suppl 1] 24: 191–196Google Scholar
  7. 7.
    Waalen K, Duff GW, Førre Ø, Dickens E, Kvarnes L, Nuki G (1986) Interleukin-1 activity produced by human rheumatoid and normal dendritic cells. Scand J Immunol 23: 365–371PubMedGoogle Scholar
  8. 8.
    Shore A, Jaglal S, Keystone EC (1986) Enhanced interleukin-1 generation by monocytes in vitro is temporally linked to an early event in the onset or exacerbation of rheumatoid arthritis. Clin Exp Immunol 65: 293–302PubMedGoogle Scholar
  9. 9.
    Danis VA, March LM, Nelson DS, Brooks PM (1987) Interleukin-1 secrection by peripheral blood monocytes and synovial macrophages from patients with rheumatoid arthritis. J Rheumatol 14: 33–39PubMedGoogle Scholar
  10. 10.
    Kean WF, Forestier F, Kassam Y, Buchanan WW, Rooney PJ (1985) The history of gold therapy in rheumatoid disease. Semin Arthritis Rheum 14: 180–186CrossRefPubMedGoogle Scholar
  11. 11.
    Situnayake RD (1988) Can disease modifying drugs influence outcome in rheumatoid arthritis? Br J Rheumatol [Suppl 1] 27: 55–65PubMedGoogle Scholar
  12. 12.
    Alexander GJ, Bacon PA, Cavalcanti F, Blake DR, Hall ND (1984) Low density lymphocytes: their relationship to disease activity and to antirheumatic therapy. Br J Rheumatol 23: 6–14PubMedGoogle Scholar
  13. 13.
    Highton J, Panayi GS, Shepherd P, Griffin J, Gibson T (1981) Changes in immune function in patients with rheumatoid arthritis following treatment with sodium aurothiomalate. Ann Rheum Dis 40: 254–262PubMedGoogle Scholar
  14. 14.
    Barrett ML, Lewis GP (1986) Unique properties of auranofin as a potential anti-rheumatic drug. Agents Actions 19: 109–115CrossRefPubMedGoogle Scholar
  15. 15.
    Drakes ML, Harth M, Galsworthy SB, McCain GA (1987) Effects of gold on the production of and response to human interleukin-1. J Rheumatol 14: 1123–1127PubMedGoogle Scholar
  16. 16.
    Danis VA, Kulesz AJ, Nelson DS, Brooks PM (1990) The effect of gold sodium thiomalate and auranofin on lipopolysaccharide-induced interleukin-1 production by blood monocytes in vitro: variation in normal subjects and patients with arthritis. Clin Exp Immunol 79: 335–340PubMedGoogle Scholar
  17. 17.
    Ropes MW, Bennett EA, Cobb S, Jacox R, Jessar R (1958) Revision of diagnostic criteria for rheumatoid arthritis. Bull Rheum Dis 9: 175–176PubMedGoogle Scholar
  18. 18.
    Fries JF, Spitz PW, Young DY (1982) The dimensions of health outcomes: The Health Assessment Questionnaire, disability and pain scales. J Rheumatol 9: 789–793PubMedGoogle Scholar
  19. 19.
    Danis VA, Kulesz AJ, Nelson DS, Brooks PM (1990) Cytokine regulation of human monocyte interleukin-1 (IL-1) productionin vitro. Enhancement of IL-1 production by interferonγ, tumour necrosis factorα, IL-2 and IL-1, and inhibition by interferonα. Clin Exp Immunol 80: 435–443PubMedGoogle Scholar
  20. 20.
    Mosmann TR, Yokota T, Kastelein R, Zurawski SM, Arai N, Takebe Y (1987) Species specificity of T cell stimulating activities of IL-2 and BSF-1 (IL-4): comparison of normal and recombinant, mouse and human IL-2 and BSF-1 (IL-4). J Immunol 138: 1813–1816PubMedGoogle Scholar
  21. 21.
    Seitz M, Deiman W, Gram N, Hunstein W, Gemsa D (1982) Characterisation of blood mononuclear cells of rheumatoid arthritis patients. I depressed lymphocyte proliferation and enhanced prostanoid release from monocytes. Clin Immunol Immunopathol 25: 405–416CrossRefPubMedGoogle Scholar
  22. 22.
    Endres S, Ghorbani R, Lonnemann G, Van Der Meer JWM, Dinarello CA (1988) Measurement of immunoreactive interleukin-1 beta from human mononuclear cells: optimization of recovery, intrasubject consistency, and comparison with interleukin-1 alpha and tumor necrosis factor. Clin Immunol Immunopathol 49: 424–438CrossRefPubMedGoogle Scholar
  23. 23.
    Mølvig J, Baek L, Christensen P et al (1988) Endotoxin-stimulated human monocyte secretion of interleukin 1, tumour necrosis factor alpha, and prostaglandin E2 shows stable inter individual differences. Scand J Immunol 27: 705–716PubMedGoogle Scholar
  24. 24.
    Santamaria P, Gehrz RC, Bryan MK, Barbosa JJ (1989) Involvement of class II MHC molecules in the LPS-induction of IL-1/TNF secretions by human monocytes. Quantitative differences at the polymorphic level. J Immunol 143: 913–922PubMedGoogle Scholar
  25. 25.
    Harth M, Davis P, Thompson JM, Menard H, Beaudet F (1987) Comparison between sodium aurothiomalate and auranofin in rheumatoid arthritis. Results of a two year open randomized study. Scand J Rheumatol 16: 177–184PubMedGoogle Scholar
  26. 26.
    Kay EA, Jayson MI (1987) Risk factors that may influence development of side effects of gold sodium thiomalate. Scand J Rheumatol 16: 241–245PubMedGoogle Scholar
  27. 27.
    Veys EM, Mielants H, Verbruggen G (1987) Gold salts, levamisole, and d-penicillamine as first choice slow-acting antirheumatic drugs in rheumatoid arthritis — a long term follow up study. Clin Exp Rheumatol 5: 111–116PubMedGoogle Scholar
  28. 28.
    Williams HJ, Dahl SL, Ward JR et al (1988) One year experience in patients treated with auranofin following completion of a parallel, controlled trial comparing auranofin, gold sodium thiomalate and placebo. Arthritis Rheum 31: 9–14PubMedGoogle Scholar
  29. 29.
    Bandilla KK, Missler B (1987) Long-term results of auranofin therapy. Clin Rheumatol [Suppl 2] 6: 35–42CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 1990

Authors and Affiliations

  • V. A. Danis
    • 1
    • 2
  • A. J. Kulesz
    • 1
    • 2
  • D. E. Kelly
    • 3
  • D. S. Nelson
    • 1
    • 2
  • P. M. Brooks
    • 3
  1. 1.Kolling Institute of Medical ResearchThe Royal North Shore HospitalSydneyAustralia
  2. 2.Department of RheumatologyThe Royal North Shore HospitalSydneyAustralia
  3. 3.Department of MedicineThe University of SydneySydneyAustralia

Personalised recommendations